At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 159 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Squamous Cell Carcinoma. Completed, enrolled 159 participants across 59 sites in 10 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic(R/M) cutaneous Squamous Cell Carcinoma (cSCC) or locally advanced (LA) unresectable cSCC that is not amenable to surgery and/or radiation and/or systemic therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma
CountriesAustralia, Canada, France, Germany, Israel, Mexico, Norway, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionJul 2020
Study CompletionSep 2023
TodayJul 2026
First PostedSep 15, 2017
Enrollment StartOct 26, 2017
Primary CompletionJul 29, 2020
Study CompletionSep 13, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.8 years ago
Interventions
Pembrolizumabbiological
IV infusion